Beta blockers should generally be held when heart rate drops below 50 beats per minute, systolic blood pressure falls below 90 mmHg with symptoms, or when certain heart rhythm abnormalities appear on an ECG. Beyond those core vital sign thresholds, several clinical situations call for temporarily pausing or reducing the dose, including acute heart failure, active wheezing, and signs of shock.
The decision to hold a dose depends on the specific reason the medication was prescribed, what’s happening with the patient right now, and how the body is responding. Here’s a breakdown of the major scenarios.
Heart Rate and Blood Pressure Thresholds
The most commonly used cutoff is a resting heart rate below 50 beats per minute. At that level, the heart may not be pumping fast enough to deliver adequate blood flow, and adding a drug that slows it further could be dangerous. Most nursing protocols and prescriber instructions flag this number as the point to hold the dose and notify the provider.
For blood pressure, a systolic reading below 90 mmHg paired with symptoms is the standard trigger. Those symptoms include dizziness, fatigue (especially when standing), lightheadedness, or fainting. A blood pressure drop of 20 points systolic or 10 points diastolic within three minutes of standing up suggests the low reading is genuinely causing problems, not just a number on a cuff. Without symptoms, a mildly low blood pressure in someone who has been stable on the medication may not require holding it, but it does warrant a conversation with the prescribing provider.
Heart Block and Rhythm Problems
Beta blockers slow electrical conduction through the heart. When that conduction is already impaired, the medication can make things worse. The key distinctions involve degrees of heart block visible on an ECG:
- Second-degree heart block: Beta blockers should be used with extreme caution and are often held, particularly in the more severe form (Mobitz type II).
- Third-degree (complete) heart block: Beta blockers are contraindicated unless the patient has a functioning pacemaker in place.
- PR interval greater than 0.24 seconds: This prolonged conduction time is listed as a contraindication in current cardiology guidelines, even if the patient hasn’t progressed to a named degree of block.
First-degree heart block on its own is not typically a reason to hold the medication, though it should be monitored.
Acute Heart Failure and Cardiogenic Shock
This is where things get nuanced. For patients who take beta blockers long-term for heart failure with reduced pumping function, the medication is one of four drug classes proven to reduce mortality. Stopping it abruptly during a hospitalization, when there’s no direct contraindication, has been linked to increased death rates and readmission. So the default in most cases is to continue it.
The exceptions are specific and serious. Current guidelines recommend holding or reducing the dose when a patient with acute decompensated heart failure has:
- Severe fluid overload that isn’t responding to treatment
- Low cardiac output, meaning the heart isn’t pumping enough blood to meet the body’s needs
- Signs of cardiogenic shock, such as cold extremities, confusion, or dangerously low blood pressure
- New or worsening heart failure symptoms that appeared after starting the beta blocker
If none of those apply, continuing the beta blocker through an acute episode is generally the safer choice. The 2025 ACC/AHA guidelines for acute coronary syndromes reinforce this approach: patients whose initial contraindication resolves within 24 hours can be restarted on a low oral dose with slow upward adjustment.
Asthma and Active Bronchospasm
Non-selective beta blockers (the older generation) are absolutely contraindicated in asthma. There are reports of severe, fatal bronchospasm from these drugs, sometimes even from eye drop formulations. If a patient with asthma is on a non-selective beta blocker and develops wheezing, the dose should be held.
Newer, heart-selective beta blockers carry less risk but still measurably affect the airways. Studies show that even a single dose of a heart-selective beta blocker reduces lung function by about 7% compared to placebo, while non-selective versions reduce it by around 10%. For someone with well-controlled, mild asthma, that small reduction may be tolerable. For someone in active bronchospasm or with poorly controlled asthma, it’s enough to tip the balance. If a beta blocker is clinically necessary for a patient with asthma, highly selective options like bisoprolol at the lowest effective dose carry the least respiratory risk.
Before Surgery
The general rule for patients already taking beta blockers before surgery is to continue them. Abruptly stopping can trigger rebound effects (more on that below), and the 2024 AHA/ACC perioperative guidelines support continuation through the surgical period for most patients. This is especially true for patients on beta blockers for heart failure, where discontinuation has clear risks.
That said, the anesthesia team may hold a dose on the morning of surgery if the patient’s heart rate or blood pressure is already low, since anesthesia itself tends to lower both. This is a judgment call made in real time based on vital signs, not a blanket policy.
Why You Shouldn’t Stop Abruptly
Suddenly discontinuing a beta blocker after regular use triggers a well-documented withdrawal response. The heart’s sensitivity to adrenaline-like signals rebounds sharply. In studies of metoprolol withdrawal, patients experienced an average 52% increase in cardiac sensitivity to stimulation and a 15% rise in resting heart rate, typically between 2 and 8 days after stopping. Some patients also developed a transient spike in blood pressure.
This rebound can be dangerous for people with underlying coronary artery disease, potentially provoking chest pain or, in rare cases, a heart attack. When beta blockers need to be discontinued, the standard approach is a gradual taper over one to two weeks rather than an abrupt stop. Even when a dose is being held temporarily for low vitals, the plan should include reassessment and resumption as soon as the patient’s numbers allow it.
Masking Low Blood Sugar in Diabetes
Beta blockers blunt the body’s early warning signals for low blood sugar. Normally, when glucose drops too low, the body releases adrenaline, causing a rapid heartbeat, sweating, and trembling that alert you to eat something. Beta blockers dampen that adrenaline response, which means a person on insulin or other diabetes medications may not feel hypoglycemia coming on until it becomes severe.
This doesn’t mean beta blockers should be routinely held in people with diabetes. It does mean that if a diabetic patient is experiencing unexplained episodes of severe low blood sugar, the beta blocker may be contributing by masking the early symptoms that would otherwise prompt a corrective snack. Closer glucose monitoring and a discussion with the prescriber about dose adjustment are appropriate steps.
How Long a Held Dose Lasts
Not all beta blockers clear the body at the same rate. Metoprolol, carvedilol, and propranolol all have relatively short half-lives, meaning their effects wear off within hours. Bisoprolol lasts longer. Atenolol falls somewhere in between, though studies suggest its true duration of action may be shorter than its once-daily dosing implies.
In practical terms, if you hold a single dose of a shorter-acting beta blocker, its blood-pressure-lowering and heart-rate-slowing effects will fade meaningfully within 12 to 24 hours. For longer-acting formulations, the effects may linger into the next day. This matters when deciding whether to hold one dose versus multiple doses, and when planning to restart.